174 related articles for article (PubMed ID: 32015308)
1. [The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)].
Dorofeev DA; Tur EV; Vizgalova LO; Tryapitsin ID; Ciganov AZ
Vestn Oftalmol; 2019; 135(6):52-59. PubMed ID: 32015308
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of antihypertensive conservative-free therapy with fixed combination of bimatoprost and timolol (intermediate results)].
Dorofeev DA; Kryzhanovskaya AV; Ciganov AZ
Vestn Oftalmol; 2020; 136(2):73-80. PubMed ID: 32366073
[TBL] [Abstract][Full Text] [Related]
3. [Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye drops].
Makashova NV; Vasilieva AE; Kolosova OY
Vestn Oftalmol; 2018; 134(2):59-65. PubMed ID: 29771886
[TBL] [Abstract][Full Text] [Related]
4. [Preservative-free betaxolol for POAG patients: evaluation of hypotensive effect and ocular surface safety].
Onischenko AL; Dimaksyan MV; Kolbasko AV; Zilina NM
Vestn Oftalmol; 2015; 131(2):76-80. PubMed ID: 26080587
[TBL] [Abstract][Full Text] [Related]
5. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review.
Skov AG; Rives AS; Freiberg J; Virgili G; Azuara-Blanco A; Kolko M
Acta Ophthalmol; 2022 May; 100(3):253-261. PubMed ID: 34128326
[TBL] [Abstract][Full Text] [Related]
7. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
[TBL] [Abstract][Full Text] [Related]
8. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
10. Ocular surface changes in primary open-angle glaucoma on anti-glaucoma medications versus treatment-naïve patients.
Srivastava K; Bhatnagar KR; Shakrawal J; Tandon M; Jaisingh K; Pandey L; Roy F
Indian J Ophthalmol; 2024 Mar; 72(3):374-380. PubMed ID: 38099355
[TBL] [Abstract][Full Text] [Related]
11. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
12. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
13. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers.
Iester M; Telani S; Frezzotti P; Motolese I; Figus M; Fogagnolo P; Perdicchi A;
J Ocul Pharmacol Ther; 2014 Aug; 30(6):476-81. PubMed ID: 24787056
[TBL] [Abstract][Full Text] [Related]
14. Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study.
Su CC; Lee YC; Lee PRC
Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1243-1251. PubMed ID: 33433642
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of ocular surface disease in glaucoma patients.
Leung EW; Medeiros FA; Weinreb RN
J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
Cho SY; Kim YY; Yoo C; Lee TE
Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
[TBL] [Abstract][Full Text] [Related]
17. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.
Dubrulle P; Labbé A; Brasnu E; Liang H; Hamard P; Meziani L; Baudouin C
J Glaucoma; 2018 Dec; 27(12):1105-1111. PubMed ID: 30489502
[TBL] [Abstract][Full Text] [Related]
18. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
19. Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.
Filippelli M; dell'Omo R; Gelso A; Rinaldi M; Bartollino S; Napolitano P; Russo A; Campagna G; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):247-253. PubMed ID: 34406502
[TBL] [Abstract][Full Text] [Related]
20. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy.
Monaco G; Cacioppo V; Consonni D; Troiano P
Eur J Ophthalmol; 2011; 21(3):243-50. PubMed ID: 20872359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
